Table 3 Clinical and laboratory features according to AQP4-AI status.

No of CSF samples

1

22

Sex

Female

All female

Age

22

40 (14-72)

Diagnosis at time of LP

rON*

NMO in 11; LETM in 6; ON in 5

IS/IM treatment at time of LP

Steroids until 5 d before LP

11/22

Disease duration in months, median

19.4

20.5 (0.1-120)

Acute attack at time of LP

Yes

19/22

AQP4-Ab serum titre, median (range)

1:1000

1000 (250-12500)

QIgG, median (range)

5.85

4.8 (1.5-16.1)

Intrathecal synthesis of total IgG

Yes

6/22

QAlb, median (range)

7.17

6.7 (3.2-31.1)

Blood-CSF barrier dysfunction

Yes

11/22